Some bladder cancer patients benefit from Roche therapy

Chicago

A NEWLY approved immunotherapy from Roche Holding proved effective as an initial treatment for some patients with advanced bladder cancer, according to data presented on Sunday.

Results of the mid-stage trial could help make the case that the drug, Tecentriq, should become the first option therapy of choice for patients with metastatic bladder cancer, according to a researcher leading the study.

Known chemically as atezolizumab, Tecentriq last month won US approval for bladder cancer that…